LobbyingOs Therapies lobbying by quarter
Os Therapies OSTX's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q3 2025; the issues it reports most are Health Issues and Pharmacy.
Os TherapiesOSTX
- Latest quarter
- $0
- Q2 2026 · 1 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q3 2025
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
Policy issues the reports name
- Health issues4 reports
- Pharmacy4 reports
A report that names several issues counts once for each.
Who was lobbied
- Food & Drug Administration (FDA)4 reports
- Health & Human Services, Dept of (HHS)4 reports
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| Chamber Hill Strategies | $0 | 4 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee; Legislative Assistant, Rep. John Thune (R-SD) | Q2 2026 |
| JENNIFER HOLLAND | Scheduler, Rep. Mary Kaptur (OH-09); Operations Director, Rep. Donald Norcross (NJ-01); Scheduler, Rep. Debbie Dingell (MI-06) | Q2 2026 |
| SHAWN FRIESEN | Legislative Director, Rep. Mac Collins (R-GA)); Legislative Assistant, Rep. Tom Ewing (IL-15); Clerk, House Judiciary Committee | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Chamber Hill Strategies | Under $5,000 |
| 04/06for Q1 | Chamber Hill Strategies | Under $5,000 |
| 01/20for Q4 2025 | Chamber Hill Strategies | Under $5,000 |
| 25/10/17for Q3 2025 | Chamber Hill Strategies | Under $5,000 |
| 25/10/16for Q3 2025 | Chamber Hill Strategies | Under $5,000 |